Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 41% Improvement Relative Risk c19early.org/d Freitas et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 490 patients in Portugal Lower mortality with higher vitamin D levels (p=0.016) Freitas et al., medRxiv, doi:10.1101/2021.03.22.21254032 Favors vitamin D Favors control
Vitamin D-related polymorphisms and vitamin D levels as risk biomarkers of COVID-19 infection severity
Freitas et al., medRxiv, doi:10.1101/2021.03.22.21254032 (Preprint)
Freitas et al., Vitamin D-related polymorphisms and vitamin D levels as risk biomarkers of COVID-19 infection severity, medRxiv, doi:10.1101/2021.03.22.21254032 (Preprint)
Mar 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Analysis of 491 hospitalized patients in Portugal showing that polymorphisms in the vitamin D binding protein encoded by the GC gene are related to COVID-19 severity (p = 0.005). There was an association between vitamin D polygenic risk score and vitamin D levels (p = 0.042), and between vitamin D levels and mortality (p = 1.5e-4). Authors conclude that a genetic susceptibility for vitamin D deficiency may explain higher severity in COVID-19.
risk of death, 41.2% lower, RR 0.59, p = 0.02, high D levels 23 of 179 (12.8%), low D levels 68 of 311 (21.9%), NNT 11, >20ng/mL.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Freitas et al., 27 Mar 2021, retrospective, Portugal, preprint, 36 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.03.22.21254032; this version posted March 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Vitamin D-related polymorphisms and vitamin D levels as risk biomarkers of COVID-19 infection severity Ana Teresa Freitas 2,3, Conceição Calhau 4,5, Gonçalo Antunes 2, Beatriz Araújo 11, Matilde Bandeira 6,15, Sofia Barreira 6,15, Filipa Bazenga 11, Sandra Braz 7, Daniel Caldeira 1,10, Susana Constantino Rosa Santos 1, Ana Faria 4, Daniel Faria 13,3, Marta Fraga 9, Beatriz Nogueira-Garcia 10, Lúcia Gonçalves 2, Pavlo Kovalchuk 2, Luísa Lacerda 11, Hugo Lopes 2, Daniel Luís 2, Fábio Medeiros 8, Ana M. P. Melo 13,14, José Melo-Cristino 9, Ana Miranda 9, Clara Pereira 2, Ana Teresa Pinto 1, João Pinto 11, Helena Proença 9, Angélica Ramos 11,12, João P. R. Rato 13,14, Filipe Rocha 1 , Júlio César Rocha 4,5, André Moreira-Rosário 4,5, Helena Vazão 2, Yuliya Volovetska 9, João-Tiago Guimarães 11,12, Fausto Pinto 1,10* 1 Centro Cardiovascular da Universidade de Lisboa (CCUL), CAML, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal; 2 HeartGenetics, Genetics and Biotechnology SA, Biocant Park, Portugal; 3 INESC-ID, Instituto Superior Técnico, University of Lisbon, Lisboa, Portugal; 4 Nutrition and Metabolism, NOVA Medical School, Universidade Nova de Lisboa, Lisboa, Portugal; 5 CINTESIS - Center for Health Technology and Services Research, Portugal; 6 Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisboa, Portugal; 7 Internal Medicine Department, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Faculdade de Medicina da Universidade de Lisboa, Portugal; 8 Department of Infectious disease, Santa Maria Hospital - CHULN, Lisboa, Portugal; 9 Clinical Pathology Department, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte, EPE, Lisbon, Portugal; 10 Cardiology Department, Hospital Universitário de Santa Maria - CHULN, Lisboa, Portugal; 11 Serviço de Patologia Clínica, Centro Hospitalar Universitário de São João, Portugal; 12 Departamento de Biomedicina, Faculdade de Medicina, EPIUnit, Instituto de Saúde Pública, Universidade do Porto, Portugal; 13 Portuguese Infrastructure of Biological Data – BioData.pt, Portugal; 14 Instituto Gulbenkian de Ciência, Oeiras, Portugal; 15 Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisboa, Portugal. * Correspondence: Fausto José da Conceição Alexandre Pinto, Centro Cardiovascular da Universidade de Lisboa (CCUL), CAML, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal, phone: +351 210 008 500, faustopinto@medicina.ulisboa.pt Conflict of interest: All authors affiliated with the company HeartGenetics, Genetics and Biotechnology SA, declare that the company developed a genetic test, the MyVitDGenes®, that was used to evaluate all the polymorphisms under analysis in this work. All other authors have declared that no conflict of interest exists. Keywords: Vitamin D deficiency, Vitamin D polymorphisms, Risk biomarkers, Population genetics, Covid-19, Covid-19 severity NOTE: This preprint reports new research..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit